Akebia Therapeutics, Inc.
AKBAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Akebia Therapeutics, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The $281.7M market capitalization puts AKBA squarely in micro-cap range for its industry. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Market Cap
$281.7M
Beta
0.35
P/E (TTM)
—
P/E (Fwd)
-5.53
EPS (TTM)
$-0.08
EPS (Fwd)
$-0.19
ROE
-79.0%
ROA
2.0%
Cash
$162.6M
Total Debt
$197.5M
Free CF
$65.8M
52W Change
-65.3%
Annual Financials
Cash vs Debt
The company holds $162.6M in cash, though total debt stands at $197.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $65.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -79.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $292.5M (2022) to $236.2M (2025), a 19% decline worth watching.
The relatively low beta of 0.35 suggests AKBA is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AKBA.